Bristol Myers Squibb Licenses In Anticancer Drug That Extends Progression-Free Survival, Why Investors Reacted Mutedly

Bristol Myers Squibb (BMY) reported positive Phase 3 trial results for its cancer drug izalontamab brengitecan, showing a median progression-free survival of 11.1 months vs. 5.7 months for chemotherapy. The drug, licensed from SystImmune, demonstrated a manageable safety profile. BMY shares rose 0.21% on the news, though investors remain cautious due to regulatory hurdles and immature overall survival data. The company paid $800M upfront and could pay up to $7.1B in milestones.

BioNTech and Bristol Myers Squibb reported Phase 2 trial results for pumitamig, an experimental lung cancer drug, showing a 36.7% response rate in advanced NSCLC patients. The trial, involving 50 patients, also reported a median progression-free survival of 6.9 months. The companies aim to address a significant unmet medical need in this patient population.

Bristol Myers Squibb (BMS) reported a patient death in its Phase I trial of zolacabtagene autoleucel for multiple sclerosis, stating it was unrelated to prior study pauses. Pathos AI partnered with BMS and Tempus AI to develop an AI-driven dataset for Alzheimer’s, with BMS leading a $237M Series E round valuing Pathos at $3B. Dr. Nadine Zawadzki discussed value-based care in healthcare on The Ron Lanton Report.

Bristol Myers Squibb reported a death in a multiple sclerosis trial of its experimental therapy zola-cel, citing late-onset motor symptoms and septic pneumonia. The company noted no other deaths in related trials. Meanwhile, the U.S. Treasury proposed new rules to scrutinize U.S. investments in China's biotech sector, potentially affecting cross-border deals.

Pathos AI has partnered with Bristol Myers Squibb (BMS) and Tempus AI to develop AI-driven drug treatments for Alzheimer’s and other neurological conditions. BMS will lead Pathos’s $237M Series E funding round, gaining access to Pathos’s Foundry platform. Tempus will provide a $55M dataset. Pathos aims to scale Foundry and advance its clinical cancer programs.

At ESMO 2026, Amgen and AstraZeneca presented data showing their combination therapy (Imdelltra + Imfinzi) reduced death risk by 58% in extensive-stage small-cell lung cancer. Roche's divarasib outperformed first-gen KRAS inhibitors in NSCLC, improving PFS and OS. MSD and Kelun-Biotech's sac-TMT with Keytruda showed PFS benefits in PD-L1-negative NSCLC. BioNTech's pumitamig showed potential in advanced NSCLC.